首页> 外文期刊>The Southeast Asian journal of tropical medicine and public health >Proguanil plus sulfamethoxazole in the treatment of uncomplicated Plasmodium falciparum malaria.
【24h】

Proguanil plus sulfamethoxazole in the treatment of uncomplicated Plasmodium falciparum malaria.

机译:丙胍加磺胺甲恶唑治疗单纯性恶性疟原虫疟疾。

获取原文
获取原文并翻译 | 示例
           

摘要

In a malaria endemic area of Brazil where P. falciparum is highly resistant to chloroquine and Fansidar, we conducted an in vivo study to evaluate the therapeutic response of proguanil plus sulfametoxazole against Plasmodium falciparum malaria. Twenty-five adult subjects with uncomplicated P. falciparum malaria received supervised drug administration and were followed for 28 days in an inpatient hospital or in a malaria free-transmission area. The therapeutic regimen was proguanil 100 mg BID plus sulfamethoxazole 1,000 mg BID for 7 days. Of those who took all medications (n=21), 17 (81%) were cured. Recrudescent parasitemia during follow-up occurred in four (19%) patients on days 14, 19, 20 and 21 after beginning of treatment. The remaining four (16%) subjects did not complete their therapeutic regimen because the incidence of side effects. Considering the shortage of falciparum malaria therapeutic options and the urgent need for new regimens to deal with the spread of drug resistant P. falciparum, onemight consider the study results as a lead to study analogous compounds, hopefully with fewer adverse reactions.
机译:在巴西的疟疾流行地区,恶性疟原虫对氯喹和Fansidar高度耐药,我们进行了一项体内研究,以评估异丙基胍和磺胺甲恶唑对恶性疟原虫疟疾的治疗反应。 25名患有单纯性恶性疟原虫疟疾的成年受试者接受了监督用药,并在住院医院或无疟疾传播区随访了28天。治疗方案为异丙酚100 mg BID加磺胺甲恶唑1,000 mg BID 7天。在所有服药者中(n = 21),有17人(81%)被治愈。在开始治疗后的第14、19、20和21天,有4名(19%)患者在随访期间发生复发性寄生虫病。剩下的四名(16%)受试者由于副作用的发生而没有完成他们的治疗方案。考虑到恶性疟疾治疗方案的短缺以及迫切需要新的方案来应对耐药性恶性疟原虫的传播,人们可能认为该研究结果是研究类似化合物的先导,希望不良反应更少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号